Computational analysis of non-covalent polymer-protein interactions governing antibody orientation.

The ALYGNSA is an affinity-based antibody orientation system produced through the interaction of the polymer poly(methyl methacrylate) (PMMA) and recombinant protein G (rProG), a streptococcal protein. This improved orientation suggests a specific non-covalent attachment of the rProG to PMMA that leaves the IgG binding region of the rProG more readily available. In this study, a full tertiary structure model of the rProG molecule of 198 amino acid residues containing a signal region, two IgG binding domains, and an anchor region, was computationally generated using the iterative threading assembly refinement (I-Tasser) server.

AFM imaging of ALYGNSA polymer-protein surfaces: evidence of antibody orientation.

Previous investigations found the combination of recombinant bacterial protein G (rProG) and poly(methyl methacrylate) (PMMA) to produce a greater proportion of oriented antibodies. PMMA-rProG yielded a sixfold greater availability of antibody Fab regions compared with other bacterial affinity linker protein and polymer pairings, including commercially available polystyrene (PS) high-binding 96-well microplates. Given the name ALYGNSA, the PMMA-rProG combination was developed into a fluorescence assay and evaluated in conjunction with commercially available cancer biomarker enzyme-linked immunosorbent assays (ELISAs).

Immuno-interferometric sensor for the detection of influenza A nucleoprotein.

Influenza A virus, both seasonal and pandemic, has the potential to cause rampant devastating disease around the world. The most relied upon methods of viral detection require days, skilled workers, and laboratory settings to complete properly. Here, we report two methods for the detection of the nucleoprotein from inactivated influenza A (IFA-NP), a patented polymer-protein antibody orientation immuno-method, termed ALYNGSA, and a newly fabricated optical label-free Fabry-Perot interferometric immunosensor.

Polymer-protein-enhanced fluoroimmunoassay for prostate-specific antigen.

Prostate-specific antigen (PSA) is a serum glycoprotein overproduced in prostate cancer, the total of which is comprised of two major forms, free and complexed. The common method for measuring of PSA is an Enzyme-linked immunosorbent assay (ELISA). Limits of detection using commercial PSA ELISA kits for free and total PSA were determined in our laboratory to be 1 and 10 ng/mL, respectively.

Novel fluoroimmunoassay for ovarian cancer biomarker CA-125.

Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.